Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Boston Scientific (BSX – Research Report), Insmed (INSM – Research Report) and Amgen (AMGN – Research Report).
Boston Scientific (BSX)
Oppenheimer analyst Steven Lichtman maintained a Hold rating on Boston Scientific today and set a price target of $68.00. The company’s shares closed last Wednesday at $63.26, close to its 52-week high of $64.49.
According to TipRanks.com, Lichtman is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific with a $69.16 average price target.
See today’s best-performing stocks on TipRanks >>
Insmed (INSM)
Wells Fargo analyst Tiago Fauth maintained a Buy rating on Insmed today and set a price target of $55.00. The company’s shares closed last Wednesday at $27.80.
According to TipRanks.com, Fauth is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insmed with a $40.71 average price target.
Amgen (AMGN)
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Amgen, with a price target of $350.00. The company’s shares closed last Wednesday at $314.26, close to its 52-week high of $316.64.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen with a $304.25 average price target, which is a -3.7% downside from current levels. In a report issued on January 25, Wells Fargo also maintained a Buy rating on the stock with a $320.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BSX:
- Boston Scientific Announces Key Executive Appointments
- Boston Scientific (NYSE:BSX) Surges on Stellar Q4 Results
- Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
- Boston Scientific sees FY24 adjusted EPS $2.23-$2.27, consensus $2.24
- Boston Scientific sees Q1 EPS 50c-52c, consensus 52c
